YOLFTbeta
00

JW Pharmaceutical Corp

001065 · KO · Healthcare / Drug Manufacturers - Specialty & Generic

20,700.00KRW+200.00 (+0.98%)

Price History

Full chart

Market Stats

Previous Close20,500.00
Open20,500.00
Day Range20,200.00 – 20,700.00
52-Week Range19,710.00 – 29,529.66
Volume54
Market Cap648.10B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield3.04%
Beta1.02
50-Day Avg22,185.00
200-Day Avg25,055.15

About

JW Pharmaceutical Corporation manufactures and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cancer, immunological disease, cardiovascular system and metabolic diseases, regenerative medicine, eye diseases , and pancreatic cancer. The company also offers infant care system, gynecological examining table, operating room equipment, steam sterilizer, and other equipment. In addition, it offers wound care, pain care, and beauty care related products. The company was founded in 1945 and is based in Gwacheon-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Young-Sub Shin
  • Employees1.05K
  • HeadquartersJW Gwacheon Tower, 38, Gwacheon-si, South Korea, 13840, Korea
  • Websitehttps://www.jw-pharma.co.kr

Leadership

  • Mr. Young-Sub ShinCEO, Head of Sales & Marketing and Inside Director · b. 1963
  • Sung-Yeol LeeCEO, Head of Product Development & Management and Director
  • Jae-Kwang JeonHead Managing Director and Head of Public Relation · b. 1962
  • Mr. Hyun-seok HanHead of Product Plant · b. 1962
  • Kim Yong KwanDevelopment Head & Internal Director

Financials

Income Statement

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue412.79B434.35B467.47B502.92B537.18B511.34B547.34B606.58B684.35B748.53B719.38B775.30B
Growth (%)-+5.22%+7.62%+7.58%+6.81%-4.81%+7.04%+10.83%+12.82%+9.38%-3.89%+7.77%
Cost of Revenue261.52B273.73B294.12B314.29B340.14B350.22B369.81B372.21B396.40B412.98B395.88B415.98B
Gross Profit151.27B160.62B173.34B188.63B197.04B161.12B177.53B234.38B287.95B335.54B323.50B359.31B
Gross Margin36.65%36.98%37.08%37.51%36.68%31.51%32.43%38.64%42.08%44.83%44.97%46.35%
Operating Expense138.04B139.10B148.81B166.91B175.46B180.13B178.85B203.18B225.18B234.63B240.77B264.85B
Operating Income13.23B21.52B24.54B21.72B21.58B-19.01B-1.32B31.20B62.78B100.92B82.73B94.46B
Operating Margin3.21%4.96%5.25%4.32%4.02%-3.72%-0.24%5.14%9.17%13.48%11.50%12.18%
EBITDA---26.32B36.60B-2.71B15.07B43.98B71.59B89.97B111.55B112.01B
EBITDA Margin---5.23%6.81%-0.53%2.75%7.25%10.46%12.02%15.51%14.45%
Net Income-2.36B1.96B-10.93B-742.47M8.06B-25.28B-15.24B-967.85M31.89B37.01B65.04B61.51B
Net Income Margin-0.57%0.45%-2.34%-0.15%1.50%-4.94%-2.78%-0.16%4.66%4.94%9.04%7.93%
R&D17.48B16.48B18.00B21.98B21.27B25.22B22.94B19.88B33.74B33.67B36.24B45.45B
R&D as % of Total Revenue4.24%3.79%3.85%4.37%3.96%4.93%4.19%3.28%4.93%4.50%5.04%5.86%
Interest Expense00008.69B11.28B7.59B7.34B9.39B12.56B10.03B4.42B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%1.62%2.21%1.39%1.21%1.37%1.68%1.39%0.57%

Balance Sheet

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets589.24B613.48B651.08B630.87B593.79B573.21B549.09B633.05B627.97B645.04B604.60B605.27B
Total Liabilities369.22B388.07B374.76B360.10B333.68B343.12B341.62B444.51B402.21B379.60B275.11B235.90B
Total Equity216.15B224.83B276.31B270.78B260.11B230.08B207.49B201.19B240.35B265.44B329.49B369.37B
Cash4.97B8.18B39.25B32.10B30.95B41.86B10.45B33.37B33.90B15.91B10.43B39.23B
Net Debt---158.26B144.27B143.27B169.60B209.18B172.54B127.23B56.07B-

Cash Flow

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow7.28B-4.17B6.74B33.45B52.11B55.53B63.05B18.12B56.76B87.16B79.39B96.40B
Investing Cash Flow10.82B-7.35B-8.77B-9.89B-13.92B-21.98B-79.43B-22.87B-18.92B---
Financing Cash Flow-14.07B14.68B33.83B-27.87B-41.19B-24.16B-14.01B27.20B-36.91B---
Capital Expenditure6.93B5.56B10.02B7.50B8.64B9.28B12.39B7.47B9.92B40.71B28.14B36.12B
Free Cash Flow---22.50B43.76B42.43B48.02B5.22B44.41B46.45B51.25B60.28B
Dividends Paid1.75B2.69B2.71B5.88B6.51B6.82B6.95B7.15B7.35B8.81B9.67B11.07B
FCF to OCF---67.26%83.99%76.42%76.15%28.81%78.24%53.30%64.56%62.53%
Dividend Paid to FCF---26.15%14.88%16.06%14.48%136.90%16.55%18.97%18.86%18.36%

Earnings

Report DateApr 3, 2009Jul 3, 2009Oct 8, 2009Mar 3, 2010Apr 2, 2010Jul 2, 2010Oct 7, 2010Mar 2, 2011Apr 8, 2011Jul 8, 2011Oct 13, 2011Feb 29, 2012Apr 6, 2012Jul 6, 2012Oct 11, 2012Feb 27, 2013Apr 5, 2013Jul 5, 2013Oct 10, 2013Feb 26, 2014Apr 4, 2014Jul 4, 2014Oct 9, 2014Feb 25, 2015Apr 3, 2015Jul 3, 2015Oct 8, 2015Mar 2, 2016Apr 8, 2016Jul 8, 2016Oct 13, 2016Mar 1, 2017Apr 7, 2017Jul 7, 2017Oct 12, 2017Feb 28, 2018Apr 6, 2018Aug 14, 2018Oct 11, 2018Feb 27, 2019Apr 5, 2019Aug 13, 2019Nov 14, 2019Feb 26, 2020May 13, 2020Aug 12, 2020Nov 12, 2020May 17, 2021Aug 17, 2021Nov 18, 2021May 17, 2022Aug 16, 2022Nov 9, 2022Mar 1, 2023May 15, 2023Aug 15, 2023Nov 15, 2023May 8, 2024Aug 1, 2024Nov 6, 2024May 7, 2025Jul 30, 2025Nov 4, 2025Dec 31, 2025May 5, 2026Jun 30, 2026
EPS Estimate------------------------------------------------------------------
EPS Actual323.99229.84-60.02224.60345.5887.4251.53-126.1688.5138.44-246.36-434.5215.44-630.44-146.81-534.7738.7250.1130.625.6876.15-243.7728.46215.0522.80-17.0846.8043.5361.51-702.68-188.52232.2334.97-42.11228.01-255.16199.58366.4699.08-323.95-199.4460.1246.55-978.43-111.88-346.98120.63164.87-137.54208.14386.8434.86333.37548.20630.19531.00-727.681035.40346.06806.95675.23-76.821266.64600.751137.701154.59
Surprise------------------------------------------------------------------
Timing---------------------------------------------------------After-hoursAfter-hoursPre-marketPre-marketPre-marketPre-market-Pre-market-

Key Statistics & Ratios

Market Cap648.10B
Enterprise Value477.76B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.84
Price / Book0.00
Revenue (TTM)820.86B
Gross Profit (TTM)388.22B
EBITDA127.31B
Profit Margin12.34%
Operating Margin15.02%
Return on Equity27.63%
Return on Assets10.78%
Shares Outstanding20.10M
Shares Float11.60M
Beta1.02
Dividend Yield3.04%
Dividend Rate675.00
Payout Ratio16.23%

Dividends

20261×
675.00Mar 31, 2026
20241×
475.00Dec 27, 2024
20231×
425.00Dec 27, 2023
20221×
380.73Dec 28, 2022
20211×
333.14Dec 29, 2021
20201×
314.02Dec 29, 2020
20191×
314.02Dec 27, 2019
20181×
314.02Dec 27, 2018
20171×
263.88Dec 27, 2017
20161×
227.94Dec 28, 2016
20151×
140.91Dec 29, 2015
20141×
115.03Dec 29, 2014
20131×
109.55Dec 27, 2013
20121×
91.29Dec 27, 2012
20111×
156.50Dec 28, 2011
20101×
215.29Dec 29, 2010
20091×
216.05Dec 29, 2009
20081×
209.75Dec 29, 2008
20071×
203.64Dec 27, 2007
20061×
93.70Dec 27, 2006
20051×
90.97Dec 28, 2005
20041×
120.43Dec 29, 2004
20031×
112.40Dec 29, 2003
20021×
72.26Dec 27, 2002

Stock Splits

  • Dec 27, 20231.02:1
  • Mar 13, 20231.03:1
  • Dec 29, 20211.03:1
  • Dec 29, 20201.03:1
  • Dec 27, 20181.02:1
  • Dec 27, 20171.02:1
  • Dec 28, 20161.02:1
  • Dec 29, 20151.05:1
  • Dec 29, 20141.05:1
  • Dec 27, 20131.05:1
  • Dec 27, 20121.05:1
  • Dec 28, 20111.05:1
  • Dec 29, 20091.03:1
  • Apr 14, 20082:1
  • Jul 2, 20070.637:1